The clinical-stage biopharmaceutical company said the payment relates to elritercept, a drug now being tested in a clinical trial. Keros recently completed the first dosing of a patient in the trial.
Despite Tuesday’s rise, the stock remains down 45% this year.

Comments (0)
No comments yet. Be the first!